Anteris Technologies Receives US FDA Approval for Transcatheter Heart Valve Trial; Shares Up 11%
MT Newswires Live
Nov 03, 2025
Anteris Technologies (ASX:AVR) received US Food and Drug Administration approval to start its Paradigm clinical trial evaluating the DurAVR transcatheter heart valve (THV) in patients with severe calcific aortic stenosis, according to a Monday filing with the Australian bourse.
Calcific aortic stenosis is a progressive heart condition where calcium deposits on the aortic valve, causing it to thicken and narrow, obstructing blood flow.
The trial will evaluate the company's DurAVR THV against commercially available transcatheter aortic valve replacements and supports a future pre-market approval application to the US FDA, per the filing.
Shares rose 11% in afternoon trade Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.